NMS Capital has exited its investment in Flourish Research, a US-based clinical trial organization, through a sale to Genstar Capital. No financial terms were disclosed.
The new Institute for Cell Therapy Discovery and Innovation will utilize expertise to develop cell therapies for cancer, autoimmune diseases, and infections.
Just one year after introducing the world’s first burn nursing specialty certification, the Board of Certification for Emergency Nursing (BCEN) proudly reports that nearly 500 nurses in both civilian ...
Three distinguished faculty members across the Purdue University system have been elected as 2024 American Physical Society (APS) Fellows, a prestigious recognition given to scientists who have made ...
Original research ranges from new concepts in human biology and disease pathogenesis to new therapeutic modalities and drug development, to all phases of clinical work, as well as innovative ...
In a report released on November 6, Brian Skorney from Robert W. Baird maintained a Hold rating on Arbutus Biopharma (ABUS – Research ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report ... based on EyePoint Pharmaceuticals’ notable advancements in their clinical trials and ...
Healthcare Asia on MSN4d
NICS building redevelopment begins in Launceston, AustraliaThe project includes the establishment of a Research and Innovation Centre. Construction has commenced on the redevelopment ...
Members of Medigene management as expert speakers, Prof. Dolores Schendel, Chief Scientific Officer and Kirsty Crame, MD, Vice President, Clinical Strategy & DevelopmentPresentations and seminars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback